These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7364141)

  • 1. Assessment of some variables affecting the blanching activity of betamethasone 17-valerate cream.
    Magnus AD; Haigh JM; Kanfer I
    Dermatologica; 1980; 160(5):321-7. PubMed ID: 7364141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment.
    Ryatt KS; Feather JW; Mehta A; Dawson JB; Cotterill JA; Swallow R
    Br J Dermatol; 1982 Jul; 107(1):71-6. PubMed ID: 7104209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of serial dilution of betamethasone-17-valerate on blanching potential and chemical stability.
    Ryatt KS; Cotterill JA; Mehta A
    J Clin Hosp Pharm; 1983 Jun; 8(2):143-5. PubMed ID: 6875011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between in vivo skin blanching and in vitro release rate for betamethasone valerate creams.
    Shah VP; Elkins J; Skelly JP
    J Pharm Sci; 1992 Jan; 81(1):104-6. PubMed ID: 1619561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
    Szadurski J; Renz F; Gasser D
    Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of betamethasone 17-valerate from extemporaneous dilutions of a proprietary topical cream.
    Magnus AD; Haigh JM; Kanfer I
    Dermatologica; 1981; 163(4):331-7. PubMed ID: 7308554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The stability and blanching efficiency of some Betnelan-V cream dilutions.
    Boonsaner P; Remon JP; De Rudder D
    J Clin Hosp Pharm; 1986 Apr; 11(2):101-6. PubMed ID: 3711358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry.
    Bjerring P
    Skin Pharmacol; 1993; 6(3):187-92. PubMed ID: 8274288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data.
    Schwarb FP; Smith EW; Haigh JM; Surber C
    Eur J Pharm Biopharm; 1999 May; 47(3):261-7. PubMed ID: 10382110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications.
    Woodford R; Haigh JM; Barry BW
    Dermatologica; 1983; 166(3):136-40. PubMed ID: 6852325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological evaluation of a new topical preparation containing dextran sulphate and betamethasone 17-valerate.
    Passarella E; Milanino R
    Arzneimittelforschung; 1980; 30(4):647-51. PubMed ID: 6156688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical betamethasone 17-valerate is an anticorticosteroid in the rat. 1. Dermal atrophy.
    Young JM; Yoxall BE; Wagner BM
    Br J Dermatol; 1978 Dec; 99(6):655-63. PubMed ID: 737128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cortisol levels in normal volunteers receiving either betamethasone valerate or desoximetasone by topical application.
    Bromley PA; Müller FO; Malan J; Torres J; Vanderbeke O
    S Afr Med J; 1978 Aug; 54(6):239-41. PubMed ID: 362568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
    Meyer E; Smith EW; Haigh JM; Kanfer I
    Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bufexamac cream versus betamethasone valerate cream in contact dermatitis: a double-blind trial.
    Wolf-Jürgensen P
    Curr Med Res Opin; 1979; 5(10):779-84. PubMed ID: 373992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for the assessment of skin atrophogenicity of topical corticosteroids.
    Marks R
    Dermatologica; 1976; 152 Suppl 1():117-26. PubMed ID: 133834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid-induced vasoconstriction in canine skin.
    Marks R; Sawyer M; Barlow JW
    Arch Dermatol Res; 1985; 277(4):318-22. PubMed ID: 4004328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical betamethasone-17-valerate inhibits heat-induced vasodilatation in man.
    Ahluwalia A; Flower RJ
    Br J Dermatol; 1993 Jan; 128(1):45-8. PubMed ID: 8427821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of systemic and topical effects of topical steroid application through the comparison of two application schedules.
    Fukaya Y; Masutani M; Koyama Y; Takahashi H; Ueda H
    J Dermatol; 1990 Jan; 17(1):28-33. PubMed ID: 2329214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of betamethasone 17 valerate on the cyclic AMP system of the pig skin epidermis.
    Ishizawa H; Iizuka H; Kajita S; Ohkawara A
    J Dermatol; 1983 Aug; 10(4):321-5. PubMed ID: 6321577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.